Pediatric-Specific Conditions That Risk Adjust

🔍 Definition

Pediatric risk adjustment refers to the statistical process of modifying capitation payments or predicted healthcare expenditures to account for the health status and expected costs of children enrolled in managed care plans. Unlike adult Medicare risk adjustment (which uses CMS-HCC v28), pediatric populations are primarily risk-adjusted under two major frameworks:

  • CDPS+Rx (Chronic Illness and Disability Payment System with Rx) — the dominant model used by state Medicaid programs for children, developed at UC San Diego. It groups diagnoses into clinical categories and assigns relative weights to predict costs for Medicaid managed care enrollees, including children with special health care needs (CSHCN).
  • HHS-HCC (Hierarchical Condition Categories for the ACA exchanges) — used under the Affordable Care Act (ACA) risk adjustment program for individual and small group commercial and exchange plans. This model includes a separate child age factor applied to condition weights, making it the primary risk adjustment model for children enrolled in ACA Marketplace plans.

Pediatric-specific conditions that risk adjust are ICD-10-CM-coded diagnoses that, when documented and coded accurately, trigger a HHS-HCC category or CDPS/Medicaid category assignment, thereby increasing the risk score and expected payment for that child’s health plan. Accurate documentation directly affects plan revenue, quality measurement, and downstream resource allocation for complex pediatric patients.

CMS-HCC v28 (the Medicare model) has extremely limited pediatric application because Medicare covers children only in rare circumstances (e.g., ESRD or certain disability categories). For the vast majority of pediatric coding and risk adjustment, coders and CDI specialists should focus on HHS-HCC (commercial/exchange) and state-specific CDPS+Rx (Medicaid).

📝 Coder Note

The HHS-HCC model uses age/sex factors applied differently for children (ages 0–20) than for adults. Conditions that have high adult HCC weights may carry even higher relative impact in the child model due to lower baseline per-member-per-month costs. Every accurately documented and coded qualifying condition can substantially affect plan reimbursement for pediatric members.

🗂️ Alternative Terminology

Clinicians, health plan staff, and coding professionals use varying terminology when discussing pediatric risk-adjusting conditions. The table below maps common alternative terms.

Formal / Technical TermColloquial / Lay / Alternative Names
Pediatric risk adjustmentChild RAF scoring; pediatric capitation adjustment; child health status payment
HHS-HCC (Hierarchical Condition Category)ACA risk adjustment HCC; exchange HCC; marketplace risk score
CDPS+RxChronic Illness and Disability Payment System; Medicaid child risk model; CDPS Medicaid categories
Children with Special Health Care Needs (CSHCN)Medically complex children; children with medical complexity (CMC); kids with special needs
Risk Adjustment Factor (RAF)Risk score; HCC score; plan liability score; risk weight
Hierarchical Condition CategoryHCC; condition category; diagnostic group
Condition weight / relative weightRAF weight; cost multiplier; severity factor
Concurrent modelCurrent-year model; same-year risk model (used in most commercial/exchange RA)
Prospective modelPrior-year model; prior-period diagnoses; forward-looking risk scoring
Pediatric obesity class / severe obesityChildhood obesity class 1, class 2, or class 3; severe obesity; BMI-for-age ≥95th percentile, ≥120% of the 95th percentile, or ≥140% of the 95th percentile, depending on class

🩺 Signs & Symptoms

Because this guide covers a spectrum of pediatric conditions rather than a single diagnosis, signs and symptoms vary by category. The following summarizes clinical presentations that should prompt coders and CDI specialists to query for risk-adjusting diagnoses:

  • Hematologic: Recurrent vaso-occlusive pain crises, acute chest syndrome, stroke/TIA in young patients (sickle cell D57.xx); prolonged bleeding, hemarthrosis, spontaneous bruising (hemophilia D66–D68).
  • Pulmonary/metabolic: Chronic productive cough, failure to thrive, recurrent pulmonary infections, pancreatic insufficiency (cystic fibrosis E84.xx); persistent wheezing, nocturnal symptoms, frequent ER visits (severe persistent asthma J45.50–J45.51).
  • Congenital/genetic: Characteristic dysmorphic features, hypotonia, developmental milestones delay, cardiac defects (Down syndrome Q90; Trisomy 13/18 Q91.x); murmur, cyanosis, poor feeding in newborns (major congenital heart disease).
  • Neurological/neuromuscular: Hypotonia, absent deep tendon reflexes, progressive weakness (spinal muscular atrophy G12.0–G12.29); proximal muscle weakness, Gowers’ sign (muscular dystrophy G71.0); recurrent seizures (epilepsy G40.x); spastic diplegia or hemiplegia (cerebral palsy G80.x).
  • Behavioral/developmental: Social communication deficits, restricted/repetitive behaviors (autism spectrum F84.0–F84.9); intellectual functioning <70 with adaptive deficits (intellectual disabilities F70–F79); inattention, hyperactivity, impulsivity with significant functional impairment and comorbidities (ADHD F90.x); speech/language regression, global developmental delay (developmental delay F88, F89).
  • Endocrine/metabolic: Polyuria, polydipsia, DKA, insulin dependence from onset (type 1 diabetes E10.x); presymptomatic/early-stage type 1 diabetes documented by staging and autoantibodies (E10.A-); BMI-for-age ≥95th percentile, acanthosis nigricans (pediatric obesity Z68.54–Z68.56 with provider-documented obesity class when applicable).
  • Growth/nutritional: Weight-for-age <5th percentile, faltering weight trajectory, inadequate caloric intake (failure to thrive R62.51; malnutrition E44.x); prematurity-related feeding difficulties (preterm newborn P07.xx).
  • Oncologic: Lymphadenopathy, unexplained fever, pallor, bruising, bone pain (leukemia/lymphoma C00–C96).
💬 CDI Query Trigger

When a child’s medical record documents recurrent hospitalizations, multiple specialists, complex medication regimens, or the use of durable medical equipment (DME), review whether underlying chronic conditions have been captured with specificity (e.g., type and severity of asthma, specific sickle cell variant, exact chromosomal disorder). These are prime indicators for concurrent risk-adjusting diagnoses that may be underreported.

🧭 Differential Diagnosis

CDI and coding professionals should consider the following differential groupings when reviewing pediatric records for risk-adjusting conditions. Not all presenting symptoms map to the highest-weighted HCC — specificity matters.

Presenting PatternConditions to ConsiderKey Differentiator
Recurrent severe infections + anemiaSickle cell disease (D57.0–D57.4x) vs. sickle cell trait (D57.3) vs. other hemoglobinopathies (D58.x)Hemoglobin electrophoresis; “trait” does NOT risk-adjust the same as “disease”
Prolonged bleeding / hemarthrosisHemophilia A (D66) vs. Hemophilia B (D67) vs. von Willebrand disease (D68.0) vs. platelet disorderFactor VIII vs. IX assay; specific factor deficiency required for HHS-HCC assignment
Recurrent pulmonary infections + FTTCystic fibrosis (E84.x) vs. primary ciliary dyskinesia (J98.09) vs. immunodeficiency (D83.x)Sweat chloride / CFTR gene testing; CF carries highest HHS-HCC weight
Developmental regression + seizuresAutism spectrum disorder (F84.0–F84.9) vs. Rett syndrome (F84.2) vs. epilepsy (G40.x) vs. SMA (G12.x)Age of onset, regression pattern, EEG, nerve conduction; multiple conditions may coexist and each codes separately
Hypotonia + motor delaySpinal muscular atrophy (G12.0–G12.29) vs. muscular dystrophy (G71.0) vs. cerebral palsy (G80.x) vs. Down syndrome (Q90)Genetic testing (SMN1/SMN2 for SMA), EMG/NCS, chromosomal microarray
Persistent wheezingSevere persistent asthma (J45.50) vs. moderate persistent (J45.40) vs. reactive airway disease vs. tracheomalaciaSeverity classification (NHLBI/GINA criteria); only “severe persistent” or “persistent” with controller therapy carries HHS-HCC weight
Elevated BMI ≥ 85th percentileOverweight (Z68.53) vs. pediatric obesity class 1 (E66.811 + Z68.54) vs. class 2 (E66.812 + Z68.55) vs. class 3 (E66.813 + Z68.56) vs. endocrine cause (hypothyroidism E03.x, Cushing E24.x)BMI-for-age percentile: Z68.53 = ≥85th to <95th; Z68.54 = ≥95th to <120% of the 95th percentile; Z68.55 = ≥120% to <140%; Z68.56 = ≥140%; rule out secondary causes
Intellectual impairmentIntellectual disability F70–F79 vs. borderline intellectual functioning (R41.83) vs. specific learning disorder (F81.x)Standardized IQ testing + adaptive behavior; F70–F79 risk-adjusts; R41.83 generally does not
Insulin-dependent diabetesType 1 DM (E10.x) vs. Type 2 DM (E11.x) vs. MODY vs. drug-induced diabetesAutoantibodies, C-peptide; type specificity drives HHS-HCC category assignment

📋 Clinical Indicators

The following clinical indicators should be verified in the medical record before assigning risk-adjusting pediatric diagnoses. Documentation must support the specificity required for the ICD-10-CM code selected.

Condition CategoryRequired Clinical IndicatorsDocumentation Source
Sickle cell diseaseHemoglobin electrophoresis confirming SS, SC, SB+/SB0 genotype; crisis type documented (vaso-occlusive, acute chest, sequestration)Lab reports, hematology notes, ED/inpatient records
HemophiliaFactor assay level; type (A=factor VIII, B=factor IX); inhibitor status; severity (mild/moderate/severe)Hematology consult, lab values, infusion records
Cystic fibrosisPositive sweat chloride ≥60 mmol/L or two CFTR mutations; pulmonary function staging; pancreatic involvementPulmonology notes, genetic reports, PFT results
Congenital disorders (Q-codes)Chromosomal/genetic confirmation; severity/type of malformation; surgical history; associated anomaliesGenetics reports, echocardiograms, surgical notes
SMA/Muscular dystrophyGenetic confirmation (SMN1/SMN2 copy number for SMA); EMG/NCS; functional classification; treatment (nusinersen, onasemnogene)Neurology notes, genetic testing, therapy records
Autism spectrum disorderFormal DSM-5 diagnosis; severity level (1–3); associated intellectual disability or language impairment coded separatelyBehavioral/developmental pediatrician, psychiatry, neuropsychological evaluation
Intellectual disabilityStandardized IQ <70; documented adaptive behavior deficits; severity level (mild F70, moderate F71, severe F72, profound F73)Neuropsychological testing, school records in EHR, psychiatry notes
Cerebral palsyType (spastic, dyskinetic, ataxic); distribution (hemiplegia, diplegia, quadriplegia); associated epilepsy or intellectual disability coded separatelyNeurology notes, physical/occupational therapy assessments
Type 1 diabetesAutoantibody positivity or very low C-peptide; presymptomatic stage if documented (E10.A-); insulin regimen when symptomatic; HbA1c; complication status (coded separately)Endocrinology notes, lab values, pump/CGM documentation
Severe persistent asthmaNHLBI/GINA severity classification documented; controller medications (high-dose ICS ± LABA/biologic); frequency of exacerbationsPulmonology or allergy notes, medication lists, ER/inpatient visit frequency
Pediatric overweight/obesityBMI-for-age percentile (CDC growth charts); age 2–20; comorbidities (sleep apnea, HTN, prediabetes); provider-documented associated diagnosis; Z68.53 for overweight and Z68.54–Z68.56 for obesity class 1–3 BMI rangesWell-child visit notes, growth charts, anthropometric measurements
CancerPrimary site, histology (pathology report); active vs. history of cancer (distinguish C vs. Z85 codes)Oncology notes, pathology, chemotherapy/radiation records
Preterm/low birth weightGestational age at birth (weeks completed); birth weight in grams; whether condition is current vs. history; neonatal complicationsDelivery records, NICU notes, neonatology documentation
Failure to thrive / MalnutritionDegree of malnutrition (mild E44.1, moderate E44.0, severe E43); etiology (protein-calorie vs. specific nutrient); dietitian assessment; weight-for-age Z-scoreDietitian notes, growth charts, lab values (albumin, prealbumin)
⚠️ Common Pitfall

Coding “reactive airway disease” or “developmental delay NOS” without clarifying specificity is a common risk-adjustment gap. Reactive airway disease documented without asthma is not coded as asthma; code the symptoms, such as wheezing (AHA Coding Clinic, 3Q 2026, “Reactive Airway Disease without Asthma”). Query providers to determine whether the child meets criteria for severe persistent asthma, autism spectrum disorder, intellectual disability, or a specific neuromuscular diagnosis. Non-specific codes (e.g., F89 Unspecified developmental disorder) carry lower or no HHS-HCC weight compared to specific diagnoses.

🦴 Anatomy & Pathophysiology

This section summarizes the pathophysiology of the major pediatric risk-adjusting condition groups to help coders understand the clinical basis for documentation specificity requirements.

Hematologic Disorders

Sickle cell disease (D57.xx): An autosomal recessive hemoglobinopathy caused by a point mutation in the beta-globin gene, resulting in hemoglobin S polymerization under hypoxic conditions. This causes red blood cell sickling, vaso-occlusion, hemolytic anemia, and progressive organ damage. The most common form (HbSS) is associated with the highest morbidity. Acute chest syndrome, stroke, splenic sequestration, and pulmonary hypertension are life-threatening complications. (NHLBI Sickle Cell Disease)

Hemophilia (D66–D68): X-linked recessive deficiency of coagulation factor VIII (Hemophilia A, D66) or factor IX (Hemophilia B, D67), resulting in impaired secondary hemostasis. Characterized by spontaneous or trauma-induced hemarthroses, intramuscular bleeds, and CNS hemorrhage in severe cases. Inhibitor development (alloantibodies to replacement factor) significantly increases treatment complexity. (CDC Hemophilia)

Pulmonary/Metabolic

Cystic fibrosis (E84.xx): Autosomal recessive disorder caused by mutations in the CFTR gene encoding the cystic fibrosis transmembrane conductance regulator chloride channel. Defective chloride transport leads to viscous mucus in airways (chronic infection, bronchiectasis, respiratory failure), exocrine pancreatic insufficiency, and infertility. The F508del mutation accounts for ~70% of CF alleles. CFTR modulators (ivacaftor, elexacaftor/tezacaftor/ivacaftor) have transformed outcomes. (Cystic Fibrosis Foundation)

Severe persistent asthma (J45.50): Chronic inflammatory airway disease characterized by hyperresponsiveness and reversible airflow obstruction. Severity classification by NHLBI EPR-3 guidelines considers daytime symptoms, nighttime awakenings, SABA use, activity limitation, FEV1/FVC, and exacerbation frequency. Severe persistent requires high-dose ICS ± adjunctive therapy; biologics (dupilumab, omalizumab, mepolizumab) now indicated for pediatric severe asthma ≥6 years.

Congenital & Chromosomal Conditions

Down syndrome (Q90.x): Trisomy 21 results in characteristic facial features, hypotonia, intellectual disability, and substantially elevated risk for congenital heart defects (40–50%, most commonly AVSD), leukemia, and hypothyroidism. Associated conditions should be coded separately. (CDC Down Syndrome)

Trisomy 13 (Q91.7) / Trisomy 18 (Q91.3): Autosomal trisomies with severe multisystem anomalies including CNS malformations, cardiac defects, and high neonatal mortality. Both are high-weight HHS-HCC categories due to extreme resource utilization.

Congenital heart disease (CHD): Structural defects of the heart or great vessels present at birth. “Major CHD” includes ventricular septal defect (Q21.0), tetralogy of Fallot (Q21.3), transposition of great vessels (Q20.3), hypoplastic left heart (Q23.4), and others. Surgical complexity and ongoing need for cardiology follow-up drive high risk-adjustment weights. (See related Congenital Heart Disease CDG)

Neuromuscular & Neurological Disorders

Spinal muscular atrophy (G12.0–G12.29): Autosomal recessive disorder caused by deletions/mutations in the SMN1 gene, causing anterior horn cell degeneration and progressive muscle weakness. SMA type 1 (Werdnig-Hoffmann, G12.0) presents in infancy with severe hypotonia; without treatment, most die before age 2. Disease-modifying therapies (nusinersen, onasemnogene abeparvovec, risdiplam) have dramatically altered the natural history. (NINDS SMA)

Muscular dystrophy (G71.0): Group of inherited myopathies; Duchenne MD (DMD) is the most common severe form, caused by dystrophin gene (Xp21) deletions, affecting ~1:3,500 male births. Progressive proximal weakness, loss of ambulation by early teens, cardiomyopathy, and respiratory failure are hallmarks. Dystrophin-targeting therapies (exon-skipping) and ataluren are in use. (CDC Muscular Dystrophy)

Cerebral palsy (G80.x): Non-progressive disorder of movement and posture resulting from damage to the developing brain. Types include spastic (most common, G80.0–G80.2), dyskinetic (G80.3), ataxic (G80.4). Associated conditions — epilepsy, intellectual disability, autism — frequently co-exist and each should be coded separately as they independently risk-adjust.

Epilepsy (G40.x): Recurrent unprovoked seizures. Code specificity requires seizure type (focal vs. generalized), intractability, and status epilepticus. Intractable epilepsy carries higher HHS-HCC weight. See the related Epilepsy CDG for full coding guidance.

Behavioral & Developmental Conditions

Autism spectrum disorder (F84.0–F84.9): Neurodevelopmental condition characterized by deficits in social communication/interaction and restricted, repetitive behaviors. DSM-5 consolidates all subtypes under ASD with three severity levels (requiring support, requiring substantial support, requiring very substantial support). Prevalence is ~1 in 36 children per CDC ADDM 2023 data. ASD maps to HHS-HCC in commercial/exchange models.

Intellectual disabilities (F70–F79): Significant limitations in intellectual functioning (IQ typically <70) and adaptive behavior, originating before age 18. Severity levels (mild, moderate, severe, profound) must be specified. The etiology should also be coded when known (e.g., Down syndrome, fragile X syndrome Q99.2).

Endocrine & Nutritional

Type 1 diabetes mellitus (E10.x): Autoimmune destruction of pancreatic beta cells, resulting in absolute insulin deficiency. Children present with DKA and require lifelong insulin therapy. Code complications when present (nephropathy, retinopathy, neuropathy, hypoglycemia) as they carry additional HHS-HCC weight. (ADA Standards of Care 2022)

Pediatric obesity (E66.811–E66.813 with Z68.54–Z68.56): For ages 2–20, pediatric BMI codes use CDC age- and sex-specific BMI-for-age thresholds, not adult BMI-only cutoffs. Z68.54 represents BMI ≥95th percentile to <120% of the 95th percentile, Z68.55 represents ≥120% to <140%, and Z68.56 represents ≥140%; obesity class codes E66.811–E66.813 may be assigned when the provider documents the class.

💊 Medication Impact / Treatment

Medications used to treat pediatric risk-adjusting conditions both confirm the diagnosis and — in some models — directly trigger risk category assignment in CDPS+Rx (which includes pharmacy data). Key medication classes and their coding implications:

ConditionKey Medications / TherapiesCoding/RA Implication
Sickle cell diseaseHydroxyurea, crizanlizumab (Adakveo), L-glutamine; chronic transfusion therapy; hematopoietic stem cell transplant; gene therapy for eligible patientsPresence of disease-modifying therapy or transfusion therapy corroborates SCD diagnosis; code causal condition, not just anemia
HemophiliaFactor VIII/IX concentrates (recombinant or plasma-derived); emicizumab (Hemlibra); desmopressin for mild hemophilia AInfusion records support hemophilia coding; inhibitor status (D66 vs. D68.311) changes code and risk weight
Cystic fibrosisCFTR modulators (ivacaftor/Kalydeco, elexacaftor/tezacaftor/ivacaftor/Trikafta); inhaled antibiotics (tobramycin, aztreonam); dornase alfa; pancreatic enzymesCFTR modulator use confirms genotype; code both E84.0 (with pulmonary manifestations) and E84.19 (with other GI) when both present
SMANusinersen (Spinraza), onasemnogene abeparvovec-xioi (Zolgensma), risdiplam (Evrysdi)Gene therapy and high-cost biologics confirm SMA diagnosis; code SMA type specifically (G12.0 type 1; G12.1 types 2, 3 [Kugelberg-Welander], and adult forms)
Muscular dystrophyCorticosteroids (deflazacort, prednisone); exon-skipping agents (eteplirsen, golodirsen, casimersen, viltolarsen); atalurenSteroid-associated complications (adrenal insufficiency, growth impairment) should be coded as additional diagnoses
Severe persistent asthmaHigh-dose ICS (fluticasone ≥500 mcg/day), ICS/LABA; biologics (omalizumab/Xolair ≥6 yr, mepolizumab/Nucala ≥6 yr, dupilumab/Dupixent ≥6 yr)Biologic therapy is indicator of severe persistent asthma (J45.50); “moderate persistent” (J45.40) does not trigger same HHS-HCC category
Type 1 DMInsulin (basal-bolus regimens); insulin pump (CSII); continuous glucose monitoring (CGM); glucagon emergency kitInsulin pump use supports Z96.41 when documented; Z79.4 identifies long-term insulin use when applicable. CGM use supports active diabetes management, but Z79.85 is for injectable non-insulin antidiabetic drugs, not CGM; code E10.- complication/status specificity
Autism / BehavioralAripiprazole (Abilify), risperidone (irritability/ASD); SSRIs; stimulants for comorbid ADHD; applied behavior analysis (ABA) therapyAntipsychotic use in children should prompt review of underlying behavioral diagnosis for RA capture; ABA billing supports ASD coding
EpilepsyLevetiracetam, valproate, lamotrigine, oxcarbazepine, clobazam; ketogenic diet; vagus nerve stimulator; responsive neurostimulationDrug-resistant/intractable epilepsy (G40.x11 or x19) carries higher weight; document intractability explicitly
Pediatric obesityMetformin (off-label); phentermine/topiramate (≥12 yr); semaglutide (Wegovy ≥12 yr); orlistat; bariatric surgery (rare ≥13 yr)GLP-1 agonist or bariatric surgery documents severity; code Z68.53 or Z68.54 based on specific BMI value
💬 CDI Query Trigger

When a child’s medication list includes high-cost specialty biologics (e.g., Spinraza, Zolgensma, Trikafta, Hemlibra, Dupixent), this is a strong signal that a high-weight risk-adjusting diagnosis should be present in the record. If the corresponding specific diagnosis code is absent or non-specific, initiate a CDI query to the prescribing provider to confirm and document the underlying condition with the required specificity.

Preview ends here. The full guide continues with FY2027 ICD-10-CM code sets, CPT surgical coding, MS-DRG mapping, reimbursement guidance, CDI query templates, and an audit checklist — all available to CCO Members.

← Back to All Clinical Documentation Guides

📘 ICD-10-CM Guidelines

The following guidelines from the FY2027 ICD-10-CM Official Guidelines for Coding and Reporting are critical for pediatric risk-adjusting conditions.

Section I.C. — Chapter-Specific Guidelines

  • Sickle cell disease (Chapter 3 — D50–D89): Code the type of crisis when present (e.g., D57.00 Hb-SS disease with crisis, unspecified; D57.01 Hb-SS disease with acute chest syndrome). “Sickle-cell trait” (D57.3) is NOT a disease — do not assign disease codes for trait carriers without clinical manifestation.
  • Diabetes mellitus (Chapter 4 — E08–E13): Type 1 DM (E10.x) should be coded with the appropriate characters to identify complications; FY2027 guidelines also recognize E10.A- for presymptomatic/early-stage type 1 diabetes. When a patient uses an insulin pump, assign Z96.41 (presence of insulin pump) as an additional code when applicable.
  • Cystic fibrosis (Chapter 4): E84.0 (CF with pulmonary manifestations) and E84.19 (CF with other GI manifestations) may be assigned together. Assign the manifestation codes additionally when documented (e.g., bronchiectasis J47.x, malabsorption K90.3).
  • Congenital malformations (Chapter 17 — Q00–Q99): Q-code conditions are always reportable, even in adults, when they continue to affect patient management. Do not assume they are “historical” once the patient is discharged from NICU.
  • Autism spectrum (Chapter 5 — F01–F99): Per DSM-5 alignment, code F84.0 (Autistic disorder) for ASD Level 1–3. When intellectual disability co-exists, assign a code from F70–F79 additionally. Language impairment (F80.x) and associated conditions should each be coded separately.
  • Intellectual disability (Chapter 5): Assign the severity code (F70–F73, F78, F79). When caused by a known condition (e.g., Down syndrome), code the underlying condition first if it is the focus of the encounter.
  • Malnutrition (Chapter 4): Malnutrition codes (E40–E46) should be assigned based on documented dietitian or physician assessment using validated tools. Coders should NOT assume or assign malnutrition from BMI/weight data alone without physician documentation.
  • Perinatal conditions (Chapter 16 — P00–P96): P07.xx codes (disorders related to short gestation and low birth weight) are used only during the perinatal period or when the condition directly affects current management in later encounters. After the perinatal period, use Z87.68 (personal history of other [corrected] conditions arising in the perinatal period) when only history is documented and the historical condition affects care.
  • Cancer (Chapter 2 — C00–D49): Active malignancy codes (C00–C96) are assigned when treatment is active. Once treatment is complete and no evidence of disease remains, assign Z85.x (history of cancer). Do NOT code “history of” with an active treatment code simultaneously.
  • BMI in children (Chapter 21 — Z68.x): Z68.5x codes are for pediatric patients ages 2–20, using BMI-for-age percentile from CDC growth charts. Z68.53 = BMI ≥85th to <95th percentile; Z68.54 = BMI ≥95th percentile to <120% of the 95th percentile; Z68.55 = BMI ≥120% to <140% of the 95th percentile; Z68.56 = BMI ≥140% of the 95th percentile. Assign BMI codes only with a provider-documented associated, reportable diagnosis such as overweight or obesity; when provider documentation supports an obesity class, use E66.811–E66.813 as appropriate and report the BMI code as an additional code.
🛡️ Audit Alert

For ACA exchange risk adjustment, all qualifying diagnoses must appear in a face-to-face encounter with an in-network provider during the data collection year. Diagnoses recorded only in lab reports, telephone encounters, or portal messages without a corresponding in-person (or qualifying telehealth) visit will NOT count toward risk score. Confirm that each risk-adjusting pediatric diagnosis is tied to a documented clinical encounter in the plan year.

Additional Coding Guidance

  • Cerebral palsy: Assign G80.x based on type and distribution. G80.0 (spastic quadriplegic), G80.1 (spastic diplegic), G80.2 (spastic hemiplegic), G80.3 (athetoid), G80.4 (ataxic). Associated epilepsy (G40.x) and intellectual disability (F70–F79) are coded additionally.
  • ADHD with comorbidities (F90.x): ADHD alone does not consistently trigger HHS-HCC assignment. When documented with significant psychiatric comorbidities (e.g., bipolar disorder F31.x, schizophrenia F20.x, conduct disorder F91.x), the comorbid condition drives the RA value. Code all documented diagnoses.
  • Developmental delay: F88 (Other disorders of psychological development) and F89 (Unspecified disorder of psychological development) are low-specificity codes. Query the provider to determine whether criteria for ASD (F84.0), intellectual disability (F70–F79), or specific developmental disorder (F80–F81) are met before assigning F88/F89.
  • Well-child visits: Z00.121 (encounter for routine child health examination with abnormal findings) triggers obligation to code the abnormal finding. Z00.129 (without abnormal findings) should be used when the child is fully healthy. If a chronic condition is monitored at the well-child visit, it should still be coded as an additional diagnosis.

🔢 ICD-10-CM Code Set (Tabular)

The following table presents the primary FY2027 ICD-10-CM codes for pediatric risk-adjusting conditions. All codes verified against the FY2027 ICD-10-CM tabular list.

ICD-10-CM CodeDescriptionHHS-HCC V08 (BY 2026, DIY Table 3)Notes
D57.00Hb-SS disease with crisis, unspecifiedHHS-HCC 70 — Sickle Cell Anemia (Hb-SS) and Thalassemia Beta ZeroUse when Hb-SS crisis is documented but the crisis type is not specified; code crisis type when known
D57.01Hb-SS disease with acute chest syndromeHHS-HCC 70 — Sickle Cell Anemia (Hb-SS) and Thalassemia Beta ZeroLife-threatening complication; distinct code
D57.02Hb-SS disease with splenic sequestrationHHS-HCC 70 — Sickle Cell Anemia (Hb-SS) and Thalassemia Beta ZeroCode separately when documented
D57.1Sickle-cell disease without crisis, Hb-SS diseaseHHS-HCC 70 — Sickle Cell Anemia (Hb-SS) and Thalassemia Beta ZeroUse when in stable phase; D57.3 (trait) does NOT map to this HCC
D57.20Sickle-cell/Hb-C disease without crisisHHS-HCC 71 — Sickle-Cell Disorders, Except Sickle-Cell Anemia (Hb-SS) and Thalassemia Beta Zero; Beta Thalassemia MajorHbSC — less severe but still RA
D57.40Sickle-cell thalassemia, unspecified, without crisisHHS-HCC 71 — Sickle-Cell Disorders, Except Sickle-Cell Anemia (Hb-SS) and Thalassemia Beta Zero; Beta Thalassemia MajorCode specific variant (SB+/SB0) when documented
D66Hereditary factor VIII deficiency (Hemophilia A)HHS-HCC 66 — Hemophilia (male); HHS-HCC 75 — Coagulation Defects and Other Specified Hematological Disorders (female)Classical hemophilia; HHS-HCC 66 for males, 75 for females; add D68.311 if inhibitor present
D67Hereditary factor IX deficiency (Hemophilia B)HHS-HCC 66 — Hemophilia (male); HHS-HCC 75 — Coagulation Defects and Other Specified Hematological Disorders (female)Christmas disease
D68.00–D68.09Von Willebrand diseaseHHS-HCC 75 — Coagulation Defects and Other Specified Hematological DisordersUse the most specific billable code: D68.00 unspecified, D68.01 type 1, D68.020–D68.029 type 2 subtypes, D68.03 type 3, D68.04 acquired, D68.09 other
E84.0Cystic fibrosis with pulmonary manifestationsHHS-HCC 159 — Cystic FibrosisAlso maps to CMS-HCC V28 HCC 277 (Cystic Fibrosis)
E84.11Meconium ileus in cystic fibrosisHHS-HCC 159 — Cystic FibrosisNeonatal presentation
E84.19Cystic fibrosis with other intestinal manifestationsHHS-HCC 159 — Cystic FibrosisCode with E84.0 when both present
E84.8Cystic fibrosis with other manifestationsHHS-HCC 159 — Cystic FibrosisIncludes other CF manifestations; for diabetes due to cystic fibrosis, code E84.- first with E08.- for diabetes mellitus due to underlying condition, using complication specificity
E84.9Cystic fibrosis, unspecifiedHHS-HCC 159 — Cystic FibrosisAvoid — use specific manifestation codes
Q90.0Trisomy 21, meiotic nondisjunctionHHS-HCC 97 — Down Syndrome, Fragile X, Other Chromosomal Anomalies, and Congenital Malformation SyndromesDown syndrome — most common chromosomal disorder
Q90.9Down syndrome, unspecifiedHHS-HCC 97 — Down Syndrome, Fragile X, Other Chromosomal Anomalies, and Congenital Malformation SyndromesUse Q90.0-Q90.2 when cytogenetic type known
Q91.3Trisomy 18, unspecifiedHHS-HCC 96 — Prader-Willi, Patau, Edwards, and Autosomal Deletion SyndromesEdwards syndrome
Q91.7Trisomy 13, unspecifiedHHS-HCC 96 — Prader-Willi, Patau, Edwards, and Autosomal Deletion SyndromesPatau syndrome
Q35.1Cleft hard palateHHS-HCC 63 — Cleft Lip/Cleft PalateSee Cleft Lip/Palate CDG
Q37.0Cleft hard palate with bilateral cleft lipHHS-HCC 63 — Cleft Lip/Cleft PalateMultiple surgical procedures; high resource utilization
Q00.0AnencephalyHHS-HCC 114 — Spina Bifida and Other Brain/Spinal/Nervous System Congenital AnomaliesSee neural tube defect coding guidance
Q05.0–Q05.9Spina bifidaHHS-HCC 114 — Spina Bifida and Other Brain/Spinal/Nervous System Congenital Anomalies; HHS-HCC 121 — HydrocephalusCode level and whether with or without hydrocephalus
Q21.3Tetralogy of FallotHHS-HCC 138 — Major Congenital Heart/Circulatory DisordersSee CHD CDG
Q20.3Discordant ventriculoarterial connection (TGA)HHS-HCC 138 — Major Congenital Heart/Circulatory DisordersTransposition of the great arteries
Q23.4Hypoplastic left heart syndromeHHS-HCC 137 — Hypoplastic Left Heart Syndrome and Other Severe Congenital Heart DisordersRequires staged surgical palliation (Norwood, Glenn, Fontan)
G12.0Infantile spinal muscular atrophy, type I (Werdnig-Hoffmann)HHS-HCC 111 — Amyotrophic Lateral Sclerosis and Other Anterior Horn Cell DiseaseMost severe SMA; gene therapy indicated
G12.1Other inherited spinal muscular atrophy (type II, III)HHS-HCC 111 — Amyotrophic Lateral Sclerosis and Other Anterior Horn Cell DiseaseG12.1 includes SMA type II, type III (Kugelberg-Welander), and adult forms; G12.21 is ALS, not SMA
G12.29Other motor neuron diseaseHHS-HCC 111 — Amyotrophic Lateral Sclerosis and Other Anterior Horn Cell DiseaseRare SMA variants; verify provider documentation of type
G71.00Muscular dystrophy, unspecifiedHHS-HCC 117 — Muscular DystrophyAvoid; use specific type below
G71.01Duchenne or Becker muscular dystrophyHHS-HCC 117 — Muscular DystrophyUse for Duchenne or Becker muscular dystrophy; most common severe dystrophinopathy group in children
G71.02Facioscapulohumeral muscular dystrophyHHS-HCC 117 — Muscular DystrophyUse for facioscapulohumeral muscular dystrophy; Becker muscular dystrophy is included in G71.01
G80.0Spastic quadriplegic cerebral palsyHHS-HCC 112 — Quadriplegic Cerebral PalsyMost severe CP type; code associated epilepsy, ID separately
G80.1Spastic diplegic cerebral palsyHHS-HCC 113 — Cerebral Palsy, Except QuadriplegicPredominantly lower extremity
G80.2Spastic hemiplegic cerebral palsyHHS-HCC 113 — Cerebral Palsy, Except QuadriplegicUnilateral involvement
G80.3Athetoid cerebral palsyHHS-HCC 113 — Cerebral Palsy, Except QuadriplegicDyskinetic; often due to kernicterus or HIE
G80.4Ataxic cerebral palsyHHS-HCC 113 — Cerebral Palsy, Except QuadriplegicCerebellar dysfunction predominant
G40.301Generalized idiopathic epilepsy and epileptic syndromes, not intractable, with status epilepticusHHS-HCC 120 — Seizure Disorders and ConvulsionsSee Epilepsy CDG; intractable = higher weight
G40.311Generalized idiopathic epilepsy and epileptic syndromes, intractable, with status epilepticusHHS-HCC 120 — Seizure Disorders and Convulsions“Intractable” = drug-resistant; document explicitly
F84.0Autistic disorder (Autism Spectrum Disorder)HHS-HCC 102 — Autistic DisorderDSM-5 ASD; code severity level via associated specifiers; comorbid ID coded separately
F84.5Asperger syndromeHHS-HCC 103 — Pervasive Developmental Disorders, Except Autistic DisorderDSM-5 subsumed under ASD; may still be documented in older records
F70Mild intellectual disabilityNo HHS-HCCIQ 50–69; code etiology when known
F71Moderate intellectual disabilityNo HHS-HCCIQ 35–49
F72Severe intellectual disabilityNo HHS-HCCIQ 20–34
F73Profound intellectual disabilityNo HHS-HCCIQ <20
F20.9Schizophrenia, unspecifiedHHS-HCC 87_1 — Schizophrenia (age >= 2)Early-onset schizophrenia (<18) is rare; document age of onset
F31.0–F31.9Bipolar disorderHHS-HCC 88 — Major Depressive Disorder, Severe, and Bipolar Disorders (age >= 2)Specify current episode type and severity
E10.9Type 1 diabetes mellitus without complicationsHHS-HCC 21 — Diabetes without Complication; HHS-HCC 22 — Type 1 Diabetes Mellitus, add-on to Diabetes HCCs 19-21 (age >= 21)Use when type 1 diabetes is documented without complications; E10.10 is type 1 diabetes mellitus with ketoacidosis without coma
E10.641Type 1 DM with hypoglycemia with comaHHS-HCC 19 — Diabetes with Acute Complications; HHS-HCC 22 — Type 1 Diabetes Mellitus, add-on to Diabetes HCCs 19-21 (age >= 21)Higher-weight subcategory
J45.50Severe persistent asthma, uncomplicatedHHS-HCC 161_1 — Severe AsthmaNHLBI step 5–6; biologic use confirms severity
J45.51Severe persistent asthma with (acute) exacerbationHHS-HCC 161_1 — Severe AsthmaCode exacerbation status
C91.00Acute lymphoblastic leukemia not achieved remissionHHS-HCC 8 — Metastatic Cancer (age >= 18); HHS-HCC 9 — Lung, Brain, and Other Severe Cancers, Including Pediatric Acute Lymphoid Leukemia (age < 18)ALL is most common pediatric cancer
C91.01Acute lymphoblastic leukemia, in remissionHHS-HCC 8 — Metastatic Cancer (age >= 18); HHS-HCC 9 — Lung, Brain, and Other Severe Cancers, Including Pediatric Acute Lymphoid Leukemia (age < 18)Still codes as active cancer during treatment
C00–C96Malignant neoplasms (all types)HHS-HCC 8–13 by site and type (cancer)Code primary site + histology; active treatment vs. history
P07.00Extremely low birth weight newborn, weight not specifiedHHS-HCC 248 — Other Premature, Low Birthweight, Malnourished, or Multiple Birth Newborns (age = 0)Newborn HHS-HCCs apply only at age 0 (infant model); no CMS-HCC V28 HCC
P07.10Other low birth weight newborn, weight not specifiedHHS-HCC 248 — Other Premature, Low Birthweight, Malnourished, or Multiple Birth Newborns (age = 0)1000–2499g range
P07.30Preterm newborn, unspecified weeks of gestationHHS-HCC 248 — Other Premature, Low Birthweight, Malnourished, or Multiple Birth Newborns (age = 0)Use specific week codes (P07.31–P07.39) when documented
R62.51Failure to thrive (child)No HHS-HCCSee related CDG; query for underlying malnutrition diagnosis
E44.0Moderate protein-calorie malnutritionHHS-HCC 23 — Protein-Calorie MalnutritionRequires dietitian or physician documentation of degree
E44.1Mild protein-calorie malnutritionHHS-HCC 23 — Protein-Calorie MalnutritionLower weight than E43/E44.0
E43Unspecified severe protein-calorie malnutritionHHS-HCC 23 — Protein-Calorie MalnutritionCode when the provider documents severe protein-calorie malnutrition; nutritional marasmus is E41 and marasmic kwashiorkor is E42
E66.811–E66.813Obesity class 1, class 2, or class 3No HHS-HCCUse provider-documented obesity class; report Z68.54–Z68.56 as additional pediatric BMI codes when documented
Z68.53BMI pediatric ≥85th-<95th percentile for ageNo HHS-HCCOverweight only; does NOT trigger morbid obesity HCC
Z68.54–Z68.56BMI pediatric obesity rangeNo HHS-HCCZ68.54 = ≥95th percentile to <120% of the 95th percentile; Z68.55 = ≥120% to <140%; Z68.56 = ≥140%; report only as an additional code with a provider-documented associated diagnosis
F90.0ADHD, predominantly inattentive typeNo HHS-HCCADHD alone = limited RA; code comorbidities fully
F90.1ADHD, predominantly hyperactive typeNo HHS-HCCSpecify type per provider documentation
F90.2ADHD, combined typeNo HHS-HCCMost common ADHD presentation in children
F88Other disorders of psychological developmentNo HHS-HCCQuery for ASD, ID, or specific developmental disorder
F89Unspecified disorder of psychological developmentNo HHS-HCCAvoid; query for specific diagnosis
Z00.121Encounter for routine child health exam with abnormal findingsNo HHS-HCCMust code the abnormal finding(s) additionally
Z00.129Encounter for routine child health exam without abnormal findingsNo HHS-HCCDo NOT use when chronic conditions are monitored
📝 Coder Note

Under the HHS-HCC concurrent risk adjustment model, ALL qualifying diagnoses reported during the benefit year (not just principal diagnoses) contribute to the risk score. This means coders should capture every active, chronic, clinically significant pediatric condition at every encounter — including preventive visits — as long as it is documented and clinically supported. Risk adjustment is not limited to inpatient claims.

🔎 Indexing

The following ICD-10-CM Alphabetic Index pathways guide coders to the correct codes for major pediatric risk-adjusting conditions. All index references are per the FY2027 ICD-10-CM Official Index.

  • Sickle cell: Disease, sickle-cell → Hb-SS → see D57.0x (with crisis subterms) or D57.1 (without crisis)
  • Hemophilia A: Hemophilia → A (classical) → D66; with inhibitor → see D68.311
  • Cystic fibrosis: Fibrosis, cystic → see E84; with pulmonary manifestations → E84.0; with meconium ileus → E84.11
  • Down syndrome: Syndrome, Down → see Q90; trisomy, 21 → Q90.0 (meiotic nondisjunction)
  • SMA: Atrophy, muscle, spinal → progressive; infantile (Werdnig-Hoffmann) → G12.0; Kugelberg-Welander → G12.1
  • Muscular dystrophy: Dystrophy, muscular → Duchenne or Becker → G71.01; facioscapulohumeral → G71.02
  • Cerebral palsy: Palsy, cerebral → spastic; quadriplegic → G80.0; diplegic → G80.1; hemiplegic → G80.2
  • Autism: Disorder, autistic → F84.0; Asperger → F84.5
  • Intellectual disability: Disability, intellectual → mild → F70; moderate → F71; severe → F72; profound → F73
  • Asthma: Asthma → severe persistent → uncomplicated → J45.50; with exacerbation → J45.51; with status asthmaticus → J45.52
  • Type 1 DM: Diabetes, type 1 → E10; with complication → see specific 4th/5th character subterms
  • Obesity (pediatric): Obesity → class 1/class 2/class 3 → E66.811–E66.813 when provider-documented; BMI → pediatric → overweight/obesity percentile ranges → Z68.53–Z68.56
  • Failure to thrive: Failure, thrive (child) → R62.51; Malnutrition → moderate protein-calorie → E44.0
  • Preterm newborn: Newborn, premature → see also P07.3x; low birth weight → P07.0x–P07.1x
  • Epilepsy: Epilepsy → generalized → idiopathic → not intractable → G40.309; intractable → G40.319

🏥 CPT

The following CPT codes are used for pediatric evaluation, management, developmental screening, and procedures related to risk-adjusting conditions. All codes verified per AMA CPT 2027.

CPT CodeDescriptionGlobal PeriodNotes / Risk Adjustment Tie-in
99381New patient preventive E&M, infant (<1 year)N/AWell-child visit; code chronic conditions additionally if present and monitored
99382New patient preventive E&M, early childhood (1–4 years)N/ADevelopmental screening expected at 9, 18, 24/30 months per AAP
99383New patient preventive E&M, late childhood (5–11 years)N/ACapture any newly identified chronic diagnoses (asthma, ASD, epilepsy)
99384New patient preventive E&M, adolescent (12–17 years)N/AScreen for behavioral health; capture F-code diagnoses for RA
99391Established patient preventive E&M, infant (<1 year)N/AUse Z00.121 if chronic condition managed; triggers RA diagnosis capture
99392Established patient preventive E&M, early childhood (1–4 years)N/AASD screening per AAP at 18 and 24 months; M-CHAT-R/F results documented
99393Established patient preventive E&M, late childhood (5–11 years)N/AChronic disease management review; confirm all active diagnoses captured
99394Established patient preventive E&M, adolescent (12–17 years)N/AObesity BMI percentile documented; Z68.54 + E66.01 when applicable
99395Established patient preventive E&M, 18–39 yearsN/AApplies to young adults 18+ in pediatric/transition practice
96110Developmental screening (e.g., Developmental Milestones Inventory, Parents’ Evaluation of Developmental Status [PEDS]), with interpretation and reportN/ASupports developmental delay / ASD documentation; M-CHAT autism screening billed here
96127Brief emotional/behavioral assessment (e.g., PHQ-9 pediatric, Vanderbilt ADHD)N/ASupports ADHD, behavioral health diagnoses; documents severity for RA
96130Psychological testing evaluation by physician/QHP, first hourN/AFormal psychological testing; supports intellectual disability coding (F70–F73)
96131Psychological testing evaluation, each additional hourN/AAppend to 96130 for extended testing sessions
99213–99215Office/outpatient E&M, established patient, varying complexityN/AFor problem-focused visits managing risk-adjusting diagnoses; captures RA codes
27422Reconstruction of quadriceps mechanism (e.g., for CP spasticity)90 daysSurgical codes for CP complications; supports G80.x coding
64642–64645Chemodenervation of extremity muscle(s); 1–4 or 5 or more muscles, including additional extremity add-on codesN/ASupports G80.x diagnosis documentation when botulinum toxin is used for CP-related limb spasticity
93303Transthoracic echocardiography for congenital cardiac anomalies; completeN/ADocuments CHD; confirms Q20–Q23 coding for major CHD HHS-HCC
33470Valvotomy, pulmonary valve, closed heart; via catheter90 daysSurgical procedure for CHD; supports Q22.1 coding
94010Spirometry, including graphic record, total and timed vital capacity, expiratory flow rate measurement(s)N/APFT supports asthma severity classification (J45.50 vs J45.40)
94640Pressurized or nonpressurized inhalation treatment for acute airway obstructionN/AAcute asthma exacerbation treatment (J45.51)
90791Psychiatric diagnostic evaluationN/AFormal psychiatric assessment; supports F20.x, F31.x, F84.0 coding
90837Psychotherapy, 60 minutesN/AOngoing behavioral health treatment; documents active psychiatric diagnoses
36430Transfusion, blood or blood componentsN/AFor sickle cell/hemophilia transfusions; supports D57.x, D66–D68 coding
📝 Coder Note

Well-child visits (99381–99395) are a critical opportunity for risk adjustment diagnosis capture. Under ACA exchange RA rules, diagnoses reported on any claim type — including preventive visits — count toward the plan year risk score. Ensure that all active, chronic, clinically significant diagnoses are listed on the claim for every encounter, including wellness visits, not just problem-focused visits.

🧾 HCPCS

HCPCS Level II codes used in pediatric risk-adjusting condition management. Codes verified against CMS HCPCS 2026 quarterly release.

HCPCS CodeDescriptionTypical Pediatric Use
G0444Annual depression screening, 15 minutesAdolescent depression screening (PHQ-A); supports F31.x, F32.x diagnosis capture
G0451Development testing, with interpretation and report, per standardized instrument formDevelopmental assessment supporting ASD (F84.0), ID (F70–F73), developmental delay (F88) coding
H0031Mental health assessment, by non-physicianBehavioral health evaluation for ASD, ADHD, bipolar, schizophrenia spectrum in children
H0032Mental health service plan development by non-physicianCare planning for F84.0, F90.x, F31.x diagnoses
H0034Medication training and support, per 15 minutesPsychotropic medication management in pediatric behavioral health
H0036Community psychiatric supportive treatment, face-to-face, per 15 minutesIntensive community-based services for severely mentally ill children (F20.x, F31.x)
H0038Self-help/peer services, per 15 minutesPeer support for adolescents with serious mental illness
H2012Behavioral health day treatment, per hourPartial hospitalization / day programs for severe pediatric psychiatric diagnoses
H2014Skills training and development, per 15 minutesApplied behavior analysis (ABA) and social skills training for ASD; supports F84.0
H2019Therapeutic behavioral services, per 15 minutesIntensive behavioral support for ASD, ID, challenging behavior
S5108Home care training to home care client, per 15 minutesTraining for caregivers of children with complex medical needs (SMA, CF, CP)
T1017Targeted case management, each 15 minutesCare coordination for CSHCN; supports documentation of multiple risk-adjusting diagnoses
J7310Ganciclovir, 4.5 mg, implantNot pediatric-specific; included for completeness
J2350Injection, ocrelizumab, 1 mg (Ocrevus)Rare pediatric MS; included for neuromuscular completeness
J0179Injection, brolucizumab-dbll, 1 mg (Beovu)Retinal disease; included for completeness
J0517Injection, benralizumab, 1 mg (Fasenra)Biologic for severe persistent asthma ≥12 yr; J45.50 diagnosis required
J0222Injection, patisiran, 0.5 mg (Onpattro)Rare hereditary TTR polyneuropathy; neuromuscular category
Q4100Skin substitute, not otherwise specifiedWound care for EB (epidermolysis bullosa Q81.x) — congenital skin fragility, RA-qualifying

📚 AHA Coding Clinic

Verified Coding Clinic, guideline, and Tabular sources for pediatric risk-adjusting conditions:

  • Sickle-cell disease (FY 2027 ICD-10-CM Tabular List; Coding Clinic, Fourth Quarter 2020; Coding Clinic, Fourth Quarter 2023): D57.1 (Sickle-cell disease without crisis) is the default for sickle-cell disease NOS. Crisis codes are type-specific, including acute chest syndrome, splenic sequestration, cerebral vascular involvement (FY 2021), and dactylitis (FY 2024). Coding Clinic, Fourth Quarter 2023, assigns D57.04 (Hb-SS disease with dactylitis) plus R50.81 for an infant with SCD, dactylitis, and fever.
  • Malnutrition (FY 2027 ICD-10-CM Official Guidelines, Section I.B.14; Coding Clinic, Third Quarter 2017): A dietitian may document the BMI, but “the associated diagnosis … must be documented by the patient’s provider.” “Severe malnutrition” indexes to E43; do not assign E40 or E42 unless kwashiorkor is specifically documented.
  • Cystic fibrosis manifestations (Coding Clinic, First Quarter 2021; FY 2027 ICD-10-CM Tabular List, E08): For a CF exacerbation with bronchiectasis, assign E84.0 as principal and J47.1 for the manifestation. For CF-related diabetes, the E08 note says “code first the underlying condition, such as cystic fibrosis (E84.-),” then the E08.- code.
  • Perinatal conditions after the newborn period (FY 2027 ICD-10-CM Official Guidelines, Section I.C.16.a.4; Coding Clinic, Third Quarter 2017): “Should a condition originate in the perinatal period, and continue throughout the life of the patient, the perinatal code should continue to be used regardless of the patient’s age.” Use Z87.68 only when the perinatal condition has resolved. ICD-10-CM does not classify infants of 37 weeks or more as preterm; do not code “late preterm infant” at 37 weeks.
  • Pediatric BMI (FY 2027 ICD-10-CM Tabular List, Z68): Pediatric BMI codes Z68.51–Z68.56 are for patients 2–19 years of age and use CDC growth-chart percentiles. Assign them only with an associated reportable diagnosis (for example, obesity) documented by the provider.

Source note: Coding Clinic items below were read in full on Find-A-Code (AHA Coding Clinic for ICD-10-CM and ICD-10-PCS). Items without a Coding Clinic issue rest on the FY 2027 Official Guidelines or Tabular List, as labeled. Codes valid as of the FY 2027 ICD-10-CM code set; HCCs per the 2024 CMS-HCC model (V28), 2027 Initial mappings.

💰 HCC / Risk Adjustment

The HHS-HCC model is the main risk adjustment model for children (child model ages 2–20; infant model ages 0–1). CMS-HCC V28 applies to Medicare beneficiaries, so it rarely applies to children; it is shown for comparison. This guide shows two models side by side. CMS-HCC V28 (the 2024 CMS-HCC model, continued for CY 2027) is used for Medicare Advantage; mappings follow the CMS 2027 Initial ICD-10-CM Mappings. HHS-HCC V08 is used for ACA individual and small-group plans; mappings follow the 2026 benefit year HHS-HCC DIY Table 3 (July 31, 2026), which covers FY 2026 codes and will be revised for FY 2027 codes. The two models use different HCC numbers; never mix them. RAF weights vary by segment and metal level and are not quoted here. Code every documented condition; CMS applies the hierarchies.

ICD-10-CM Code(s)DescriptionCMS-HCC V28 (Medicare Advantage)HHS-HCC V08 (ACA, BY 2026)Coding / Documentation Notes
E84.0–E84.9Cystic fibrosisHCC 277 — Cystic FibrosisHCC 159 — Cystic Fibrosis—
D57.00–D57.1Sickle cell disease Hb-SS, with or without crisisHCC 107HCC 70 — Sickle Cell Anemia (Hb-SS) and Thalassemia Beta ZeroInfant models assign HCC 70 and 71 a higher severity
D57.20–D57.819Hb-SC disease, sickle-cell thalassemia, other sickle-cell disordersHCC 108HCC 71 — Sickle-Cell Disorders, Except Sickle-Cell Anemia (Hb-SS) and Thalassemia Beta ZeroD57.3 (trait) maps in neither
D66, D67Hemophilia A and BHCC 111 (female: 112)HCC 66 — Hemophilia (male); HCC 75 (female)Sex split in both models
G12.0, G12.1Infantile and other inherited spinal muscular atrophyHCC 190HCC 111 — Amyotrophic Lateral Sclerosis and Other Anterior Horn Cell Disease—
G71.00–G71.09Muscular dystrophyHCC 197HCC 117 — Muscular Dystrophy—
G80.0; G80.1–G80.9Spastic quadriplegic cerebral palsy; other cerebral palsyHCC 191; HCC 192HCC 112 — Quadriplegic Cerebral Palsy; HCC 113 — Cerebral Palsy, Except Quadriplegic—
G40.-EpilepsyHCC 201HCC 120 — Seizure Disorders and Convulsions—
F84.0; F84.5, F84.9Autistic disorder; Asperger syndrome, pervasive developmental disorder unspecifiedNo V28 payment HCCHCC 102 — Autistic Disorder; HCC 103 — Pervasive Developmental Disorders, Except Autistic Disorder—
F90.-, F70–F79ADHD; intellectual disabilitiesNo V28 payment HCCNo HHS-HCC—
E10.-Type 1 diabetesHCC 36–38 by complicationHCC 19–21 by complication (adults 21+ also get add-on HCC 22)—
J45.50–J45.52, J45.42Severe persistent asthma; moderate persistent asthma with status asthmaticusJ45.5-: HCC 279; J45.42: no V28 HCCHCC 161_1 — Severe AsthmaOther asthma codes: HCC 161_2 (Asthma, Except Severe)
E43, E44.0Severe and moderate protein-calorie malnutritionNo V28 payment HCCHCC 23 — Protein-Calorie MalnutritionR62.51 (failure to thrive) maps in neither
P07.00–P07.39, P05.0-, Z38.-Prematurity and low birth weight; light for dates; liveborn infantNo V28 payment HCCHCCs 242–249 (newborn birthweight and maturity HCCs; age 0 only)Infant model combines a maturity category with a severity level

Many HHS-HCC CCs have age splits (for example, a code that maps to one HCC under age 2 and another at age 2 or older). Check the CC Age Split column in DIY Table 3. V24 numbers such as HCC 48, 75, 79, 82, and 85 do not apply in either current model.

🛡️ Audit Alert — Newborn HCCs

Newborn birthweight and maturity HCCs (242–249) apply only in the infant model at age 0. When a hospital bills mother and newborn on one claim, the DIY instructions explain how the newborn and delivery HCCs are separated; follow the payer’s claim rules.

Sources: CMS 2027 Initial ICD-10-CM Mappings (CMS-HCC V28); CMS CY 2024 Rate Announcement, Attachment VI (V28 labels and hierarchies); CMS 2026 Benefit Year HHS-HCC DIY Software Instructions and Tables 3 and 4 (July 31, 2026); FY 2027 ICD-10-CM Tabular List, Index, and Official Guidelines. Verified November 3, 2026.

✍️ CDI Query Templates

The following query templates are designed to be compliant with AHIMA/ACDIS CDI query guidelines — non-leading, multiple-choice, clinician-driven. Queries should be presented as formal documentation requests, not suggestions of a specific answer.

ScenarioQuery Wording (Non-Leading, Multi-Choice)
Child with recurrent wheezing, ICS/biologic therapy, no severity specified“Based on the patient’s documented symptom frequency, nighttime awakenings, activity limitation, FEV1 results, and current controller medication regimen (including [biologic name]), can you clarify the asthma severity classification? Options: (a) Intermittent, (b) Mild persistent, (c) Moderate persistent, (d) Severe persistent, (e) Clinically undetermined.”
Child with developmental concerns, behavioral therapy, no specific diagnosis“The record documents behavioral therapy and developmental concerns. Based on your clinical evaluation, does this patient’s presentation meet criteria for: (a) Autism spectrum disorder (specify severity level if applicable), (b) Intellectual disability (specify degree if applicable), (c) Specific developmental disorder (language/speech/learning), (d) Attention-deficit/hyperactivity disorder, (e) Other specified developmental disorder (F88), (f) Clinically undetermined.”
Child with sickle cell disease, hospitalized for pain crisis, type not documented“This patient was admitted with acute pain in the setting of known sickle cell disease. Based on the clinical presentation and workup, can you identify the type of crisis, if any? Options: (a) Vaso-occlusive pain crisis, (b) Acute chest syndrome, (c) Splenic sequestration, (d) Stroke/CNS crisis, (e) No specific crisis — uncomplicated sickle cell disease, (f) Other (specify), (g) Clinically undetermined.”
Child with poor weight gain, low weight-for-age, no malnutrition documented“The record documents weight-for-age below the 5th percentile with inadequate caloric intake. Based on your clinical assessment, does this patient’s nutritional status represent: (a) No malnutrition, (b) Mild malnutrition (E44.1), (c) Moderate malnutrition (E44.0), (d) Severe protein-calorie malnutrition / marasmus (E43), (e) Failure to thrive without malnutrition (R62.51), (f) Clinically undetermined.”
Child with BMI ≥95th percentile on growth chart, no obesity diagnosis documented“The growth chart documents BMI at or above the 95th percentile for age and sex. Based on your clinical assessment, does this patient have: (a) Overweight (BMI 85th–<95th percentile, Z68.53), (b) Obesity class 1 (BMI ≥95th percentile to <120% of the 95th percentile, E66.811 + Z68.54), (c) Obesity class 2 (BMI ≥120% to <140% of the 95th percentile, E66.812 + Z68.55), (d) Obesity class 3 (BMI ≥140% of the 95th percentile, E66.813 + Z68.56), (e) Overweight/obesity attributable to a secondary medical cause (specify), (f) Clinically undetermined.”
Child with intellectual impairment receiving special education, no IQ documented in chart“The record references special education services and learning difficulties. Based on psychological testing or clinical evaluation, does this patient have: (a) Mild intellectual disability (IQ approximately 50–69, F70), (b) Moderate intellectual disability (IQ approximately 35–49, F71), (c) Severe intellectual disability (IQ approximately 20–34, F72), (d) Profound intellectual disability (IQ <20, F73), (e) Borderline intellectual functioning (IQ 70–84, R41.83), (f) Specific learning disorder (F81.x), (g) Clinically undetermined.”
Infant on nusinersen/Zolgensma, SMA type not documented“This patient is receiving [nusinersen/onasemnogene abeparvovec/risdiplam] for spinal muscular atrophy. Based on the genetic testing and clinical presentation at diagnosis, what is the SMA type? Options: (a) SMA Type I — Werdnig-Hoffmann (G12.0), (b) SMA Type II (G12.1), (c) SMA Type III — Kugelberg-Welander (G12.1), (d) SMA Type IV — adult onset (G12.1), (e) SMA pre-symptomatic (genetic diagnosis only), (f) Clinically undetermined.”
Child with epilepsy on multiple AEDs, intractability not documented“This patient is on [list AEDs] for documented epilepsy. Based on the seizure frequency and response to antiepileptic therapy, is the epilepsy: (a) Controlled/not intractable, (b) Drug-resistant/intractable (poorly controlled despite ≥2 adequate AED trials), (c) Clinically undetermined.”
💬 CDI Query Trigger

For children receiving Medicaid-funded HCBS (Home and Community Based Services) waiver services, the qualifying diagnosis driving the waiver (e.g., G80.x for CP waiver, G12.x for SMA waiver, F84.0 for autism waiver) should be present in the medical record with specificity. The waiver documentation itself is strong evidence to support the qualifying diagnosis — cross-reference with the EHR for coding completeness.

🧑‍⚕️ Treatments (Clinical)

The following summarizes current evidence-based treatment approaches for major pediatric risk-adjusting conditions. This section provides clinical context to help CDI specialists understand what constitutes active, ongoing management requiring continued diagnosis coding.

Sickle Cell Disease

Management includes hydroxyurea (first-line disease-modifying agent for HbSS/HbSβ⁰), crizanlizumab for vaso-occlusion prevention in eligible patients, L-glutamine, chronic transfusion therapy for stroke prevention, hematopoietic stem cell transplant (HSCT), and gene therapy approaches such as betibeglogene autotemcel/Zynteglo and exagamglogene autotemcel/Casgevy for eligible patients. Voxelotor/Oxbryta is no longer listed as an active treatment because it was voluntarily withdrawn from the market in 2024 due to safety concerns.

Cystic Fibrosis

CFTR modulator therapy has transformed CF management for patients with eligible mutations. Elexacaftor/tezacaftor/ivacaftor (Trikafta/Kaftrio) is approved for patients ≥2 years with at least one F508del allele, achieving sustained FEV1 improvement and dramatic reduction in exacerbations. Airway clearance therapy (ACT), inhaled antibiotics, pancreatic enzyme replacement therapy (PERT), and CF dietitian management remain foundational components. Lung transplant for advanced disease.

Spinal Muscular Atrophy

Disease-modifying therapies include: intrathecal nusinersen (Spinraza, approved all ages and types), IV onasemnogene abeparvovec-xioi (Zolgensma, approved <2 years or <21 kg), and oral risdiplam (Evrysdi, approved ≥2 months). Multidisciplinary care includes respiratory support (non-invasive ventilation, cough assist), nutritional management (gastrostomy tube), and orthopedic management (scoliosis, contractures). Early treatment of pre-symptomatic SMA (newborn screening) has become standard of care in states with NBS programs. (NINDS SMA)

Cerebral Palsy

Multidisciplinary management focuses on maximizing function: physical therapy (PT), occupational therapy (OT), speech-language pathology (SLP), orthotics/AFOs, intrathecal baclofen pump (ITB) for spasticity, selective dorsal rhizotomy (SDR), botulinum toxin injections (BTX-A), and orthopedic surgery (hip reconstruction, hamstring lengthening). Associated epilepsy managed with AEDs; associated ID with educational and behavioral supports.

Autism Spectrum Disorder

Evidence-based interventions include applied behavior analysis (ABA) — the most extensively studied behavioral intervention for ASD — early intensive behavioral intervention (EIBI), speech-language therapy, occupational therapy, social skills training, and family support/caregiver training. Pharmacotherapy (aripiprazole, risperidone) for irritability/self-injurious behavior associated with ASD. No FDA-approved treatment for core ASD symptoms. (AAP Autism Guidance)

Type 1 Diabetes Mellitus

Insulin therapy is required for symptomatic type 1 diabetes (multiple daily injections or continuous subcutaneous insulin infusion/CSII). Continuous glucose monitoring (CGM) and automated insulin delivery should be considered based on the child’s and family’s circumstances, capabilities, and access. Per ADA Standards of Care 2026, A1C goals must be individualized and an A1C of <7% is appropriate for most children and adolescents with diabetes; complication screening should follow current ADA pediatric recommendations.

Severe Persistent Asthma

NHLBI EPR-3/GINA step 5–6 therapy: high-dose ICS + LABA as foundation; add-on biologics for eligible patients ≥6 years (anti-IgE: omalizumab; anti-IL-5: mepolizumab/reslizumab; anti-IL-5Rα: benralizumab; anti-IL-4Rα: dupilumab; anti-TSLP: tezepelumab ≥12 years). Allergen immunotherapy as adjunct. Bronchial thermoplasty not approved for children. Pulmonology/allergy co-management recommended. Asthma action plan, spacer use, avoidance counseling.

🎓 Patient Education / Summary

For CDI and coding teams working with pediatric practices and health plans, the following key takeaways summarize the risk adjustment coding priorities for children with complex chronic conditions:

For Coding and CDI Teams

  • Model awareness: Children on ACA exchange plans are subject to HHS-HCC concurrent risk adjustment. Children on Medicaid MCO plans are primarily subject to state CDPS+Rx models. Understanding which model applies determines which code categories drive payment.
  • Capture at every encounter: Unlike adult Medicare, HHS-HCC is concurrent — diagnoses from any encounter type (preventive, acute, specialist) during the benefit year count. Document and capture all chronic conditions at every qualifying visit.
  • Specificity matters: Non-specific codes (F89, J45.9, G80.9) carry lower or no HCC weight. Query providers to elevate to specific codes (F84.0, J45.50, G80.0) that trigger appropriate HCC assignment.
  • Co-morbidities stack: A child with cerebral palsy, epilepsy, and intellectual disability has three independently risk-adjusting diagnoses. Each must be supported by documentation and coded at every encounter where each condition affects management.
  • Well-child visit opportunity: The annual well-child exam is the highest-yield encounter for risk adjustment capture because ALL active conditions are typically reviewed. Ensure the claim reflects every chronic condition reviewed during the visit.
  • Documentation required: Medication lists and problem lists alone do NOT support risk adjustment claims — only face-to-face encounter notes with supporting clinical documentation. CDI teams should focus on ensuring narrative encounter notes explicitly support each diagnosis code.

Patient / Family Education Points

When preparing patient and family education materials related to complex pediatric conditions that risk-adjust:

  • Explain the importance of attending ALL scheduled appointments — primary care, specialist, behavioral health — as each encounter captures the conditions that help ensure adequate resources and coverage for your child’s care.
  • Maintain an up-to-date, written diagnosis list including all chronic conditions, medications, and specialists. Bring this to every appointment so the team can document all active conditions.
  • Understand that “administrative” diagnoses (the codes on your child’s insurance claims) must reflect what is happening clinically. If your child’s diagnoses have become more or less specific, work with your care team to update documentation.
  • For children transitioning from pediatric to adult care (typically age 18–21), ensure that diagnoses are transferred accurately to the new adult provider’s documentation system and that ACA/Medicaid enrollment transitions are managed to preserve continuity of risk-adjustment coding.
  • Families of children with CSHCN can contact their health plan’s care management team or state CSHCN program for coordination support. Organizations such as Family Voices and the Association of Maternal and Child Health Programs (AMCHP) provide resources for navigating complex pediatric healthcare.
📝 Coder Note

Pediatric risk adjustment is an evolving area. CMS updates HHS-HCC model coefficients annually through the Notice of Benefit and Payment Parameters (NBPP). State Medicaid programs update their CDPS+Rx models on varying schedules. Coders and CDI professionals should stay current with the applicable model year for each payer to ensure risk-adjustment coding is optimally capturing condition weights for pediatric enrollees.


About this Guide

This Clinical Documentation Guide is published by CCO Academy and is intended for credentialed coding, CDI, and clinical documentation professionals. Content is updated for FY2027 ICD-10-CM (effective October 1, 2026) and CPT 2027. All code assignments should be verified against the official ICD-10-CM Tabular List, AHA Coding Clinic, AMA CPT, and applicable payer-specific policies. This guide does not constitute legal, medical, or compliance advice.

Last reviewed: April 2026 · Next scheduled review: October 2026 (FY2027 update)

Ready to turn this knowledge into a credential?

These Clinical Documentation Guides are a free companion to CCO’s paid training programs. Browse our full CCO Course, Blitz & Practice Exam Catalog — every core course, review blitz, practice exam, textbook, and free resource in one place — and find the perfect next step for your coding career.

CCO Hero

Know someone starting a medical coding career?

Share your personal CCO link. Your friend saves 20% on their first course or practice exam of $100 or more, and you earn 5% cash on their first enrollment over $100.

Become a CCO Hero
Photo of author

CCO Certified Professionals

The CCO Certified Professionals team brings together experienced, credentialed medical coders, CDI specialists, and clinical documentation experts with decades of combined expertise in inpatient, outpatient, and risk-adjustment coding. Every Clinical Documentation Guide is built and reviewed by certified instructors who teach, code, and audit in the field every day. Content is verified against current ICD-10-CM, AHA Coding Clinic, and CMS guidance.

Leave a Comment

Clinical Doc Guides

⚊